By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

Novo Nordisk's experimental drug, CagriSema, shows promise beyond weight loss, potentially offering significant ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help ...

People who have tried medication to lower their dangerously high levels of cholesterol and other blood fats – without success ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...

The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need ...

Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...

For people with Type 2 diabetes, following at least six healthy lifestyle habits when taking GLP-1 RA medications can lower their risk of heart attack, stroke, hospital visits due to cardiovascular ...

Older adults face unique barriers in hypertension management, including comorbidities, mobility limitations, and medication adherence challenges, impacting digital health tool effectiveness. Trials ...